First-line treatment of metastatic breast cancer with the use of liposomal doxorubicin (Myocet ® ) in a female patient with ischaemic heart disease and cardiac dysrhythmia

Abstract

Anthracyclines are drugs characterised by high efficacy in the treatment of patients with metastatic breast cancer. However, this therapeutic approach is contraindicated in some of the female patients with a history of heart disease in view of the risk of cardiotoxicity. A case report is presented of a female patient with ischaemic heart disease and cardiac dysrhythmia receiving liposomal doxorubicin as part of the first-line treatment of metastatic breast cancer.
Onkol. Prak. Klin. 2010; supl. A: A31–A32